Sorivudine

Phase 3Small molecule

Bristol-Myers Squibb

Sorivudine is one of 55 small molecule programs targeting Viral Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Viral DiseaseActive, not recruiting

Viral DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Viral Disease

#DrugCompanyPhaseTrials

Videx

Selzentry

Emtriva

Vemlidy

Hepsera

Tivicay

Vistide

Xofluza

Incivek

Vertex Pharmaceuticals

Famvir

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Viral Disease1 trial

A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00002358

Treatment1 trial

Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000953·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sorivudine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sorivudine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sorivudine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Sorivudine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Viral Disease1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News